Schott Pharma and Nemera launch combined self-injection syringe system
Schott Pharma and Nemera have launched a passive safety system pairing Schott's 5.5ml syriQ BioPure prefillable glass syringe with Nemera's Safe'n'Sound safety device, targeting subcutaneous self-injection of large-volume biologic drugs. The companies say the pre-aligned platform is already available for technical assessment and compatibility studies, and will be shown at CPHI Milan and PDA in early October 2026. They describe it as the first such combination built around a 5.5ml prefillable glass syringe.
Why this mattersA pre-validated syringe-and-safety-device combination lowers technical risk for biologics makers shifting therapies from intravenous to home subcutaneous delivery.
- The system pairs Schott Pharma's 5.5ml syriQ BioPure prefillable glass syringe with Nemera's Safe'n'Sound passive safety device.
- Launch was announced 22 September 2026.
- The companies describe it as the industry's first passive safety system built around a 5.5ml prefillable glass syringe.
- It targets subcutaneous self-injection of large-volume and biologic drugs, including homecare use.
- The product will be exhibited at CPHI Milan on 6-8 October 2026 and PDA 2026 on 6-7 October 2026.
- It is already available for technical assessment, compatibility studies and development programmes.
Sources
nemera.net